Hosted on MSN10mon
Novartis allies with Voyager to develop gene therapies in $1.3bn dealThe agreement allowed Novartis access to Voyager’s technology to develop AAV capsids for use against diseases that affect the central nervous system and the option for two additional targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback